The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of adverse events (AEs)
Timeframe: Up to approximately 2 years
Incidence of serious adverse events (SAEs)
Timeframe: Up to approximately 2 years
Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria
Timeframe: Up to approximately 28 days
Incidence of AEs leading to discontinuation
Timeframe: Up to approximately 2 years
Incidence of AEs leading to death
Timeframe: Up to approximately 2 years